title: [Comparison of liver resection with sequential transarterial chemoembolization in stage pT3 or pT4 hepatocellular carcinoma].
abstract: Between January 1990 and January 1996, 39 consecutive patients with histologically improved pT3 or pT4 HCC tumors underwent curative resection (n = 19) or sequential transarterial chemoembolization (n = 20) with a median time interval of 7 weeks up to six times with an emulsion of Lipiodol, Epirubicin and Cisplatin. The 30-day mortality rate for all sessions of TA was 3.8% vs. 21.8% in the resection group (p < 0.05); the cumulative survival rate for the embolization group at 6, 12, 18 and 24 months was 72.3%, 50.1%, 41.2%, 35.4% vs. 42.1%, 31.6%, 31.6% and 14.2% following resection, which cannot be considered statistically significant. Patients with T3 and T4 HCC, treated with sequential embolization or resection, seem to have a comparable survival time.
authors.affiliation: Chirurgische Klinik, Städtische Kliniken Dortmund.
authors.forename: F
authors.initials: F
authors.lastname: Hasse
authors.forename: U M
authors.initials: UM
authors.lastname: Mehring
authors.forename: F
authors.initials: F
authors.lastname: Castaneda
authors.forename: H
authors.initials: H
authors.lastname: Jäger
authors.forename: K D
authors.initials: KD
authors.lastname: Mathias
authors.forename: D
authors.initials: D
authors.lastname: Löhlein
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006498:Hepatectomy; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
chemical_list: D015251:Epirubicin; D007459:Iodized Oil; D002945:Cisplatin
vernacular_title: Vergleich der Leberresektion gegenüber der sequentiellen transarteriellen Chemoembolisation bei Hepatozellulären Karzinom im Stadium pT3 oder pT4.